Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13238MR)

This product GTTS-WQ13238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13238MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15675MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ5173MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ7989MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ5230MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ2457MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ15897MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ11209MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ13032MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.